BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun 2021;27:100328. [PMID: 33549983 DOI: 10.1016/j.ctarc.2021.100328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Hamidi-sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E. Oncolytic viruses and pancreatic cancer. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100563] [Reference Citation Analysis]
2 Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Regmi P, He Z, Lia T, Paudyal A, Li F. N7-Methylguanosine Genes Related Prognostic Biomarker in Hepatocellular Carcinoma. Front Genet 2022;13:918983. [DOI: 10.3389/fgene.2022.918983] [Reference Citation Analysis]
4 Chen Z, Ma Y, Guo Z, Song D, Chen Z, Sun M. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100669] [Reference Citation Analysis]
5 Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol 2022. [PMID: 35378995 DOI: 10.2217/fon-2021-1647] [Reference Citation Analysis]
6 Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14:1404. [PMID: 35326555 DOI: 10.3390/cancers14061404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zheng X, Shao J, Wei S, Gu Y, Qian J. Prognostic Significance of SOCS3 in Patients With Solid Tumors: A Meta-Analysis. Front Surg 2022;8:802143. [DOI: 10.3389/fsurg.2021.802143] [Reference Citation Analysis]
8 Paschou SA, Liontos M, Eleftherakis-papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos M. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Front Oncol 2022;12:847917. [DOI: 10.3389/fonc.2022.847917] [Reference Citation Analysis]
9 Lee DH, Hwang S, Koh YH, Lee KH, Kim JY, Kim YJ, Yoon JH, Lee JH, Park JW. Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST? Front Med (Lausanne) 2021;8:771887. [PMID: 34966757 DOI: 10.3389/fmed.2021.771887] [Reference Citation Analysis]
10 Zhu S, Chen Y, Ye H, Wang B, Lan X, Wang H, Ding S, He X. Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100678] [Reference Citation Analysis]
11 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Reference Citation Analysis]
12 Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, Marco MD, Gadaleta-Caldarola G, Brandi G. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35109664 DOI: 10.2217/fon-2021-0905] [Reference Citation Analysis]
13 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Reference Citation Analysis]
14 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
15 Zheng W, Sun G, Li Z, Wu F, Sun G, Cao H, Zhou J, Ma Y. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. Front Surg 2022;9:895982. [DOI: 10.3389/fsurg.2022.895982] [Reference Citation Analysis]
16 Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Current Oncology 2022;29:3259-71. [DOI: 10.3390/curroncol29050266] [Reference Citation Analysis]
17 Luo R, Li Y, Wu Z, Zhang Y, Luo J, Yang K, Qin X, Wang H, Huang R, Wang H, Luo H. Comprehensive Analysis of Microsatellite-Related Transcriptomic Signature and Identify Its Clinical Value in Colon Cancer. Front Surg 2022;9:871823. [DOI: 10.3389/fsurg.2022.871823] [Reference Citation Analysis]
18 Ren Q, Zhu P, Li C, Yan M, Liu S, Zheng C, Xia X. Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor. Front Bioeng Biotechnol 2022;10:872044. [DOI: 10.3389/fbioe.2022.872044] [Reference Citation Analysis]
19 Liu X, Liu F, Yu H, Zhang Q, Liu F. Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma. IJGM 2022;Volume 15:3625-37. [DOI: 10.2147/ijgm.s351265] [Reference Citation Analysis]
20 Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A, Bogale A, Chekol Abebe E. Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. JIR 2022;Volume 15:1349-64. [DOI: 10.2147/jir.s353489] [Reference Citation Analysis]
21 Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Reference Citation Analysis]
22 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Huang JL, Chang YT, Hong ZY, Lin CS. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. Int J Mol Sci 2022;23:3238. [PMID: 35328658 DOI: 10.3390/ijms23063238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Reference Citation Analysis]
25 Fan X, Gu L, Lv S, Zhang M, Zhuang L, Zhang Y, Chen P. Suppression of the transforming growth factor-β signaling pathway produces a synergistic effect of combination therapy with programmed death receptor 1 blockade and radiofrequency ablation against hepatic carcinoma in mice. Bioengineered 2022;13:9046-58. [PMID: 35354382 DOI: 10.1080/21655979.2022.2051688] [Reference Citation Analysis]
26 Rizzo A. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35193371 DOI: 10.2217/fon-2021-1623] [Reference Citation Analysis]
27 Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 2021;:1-7. [PMID: 34793275 DOI: 10.1080/13543784.2022.2008354] [Reference Citation Analysis]
28 Huang T, Chen X, Zhang H, Liang Y, Li L, Wei H, Sun W, Wang Y. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:706652. [PMID: 34395281 DOI: 10.3389/fonc.2021.706652] [Reference Citation Analysis]
29 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Li W, Han L, Xiao B, Li X, Ye Z. A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection. Diagnostics 2022;12:1073. [DOI: 10.3390/diagnostics12051073] [Reference Citation Analysis]
31 Huang J, Kang W, Pan S, Yu C, Jie Z, Chen C, Ciccarone F. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6891155] [Reference Citation Analysis]
32 Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey J, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers 2022;14:1901. [DOI: 10.3390/cancers14081901] [Reference Citation Analysis]
33 Rizzo A, Ricci AD, Brandi G. Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development 2022;7:1-3. [DOI: 10.1080/23808993.2022.2020091] [Reference Citation Analysis]
34 Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1195-207. [PMID: 34595140 DOI: 10.2147/JHC.S322289] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]